BriaCell: Strong Clinical Data in Breast Cancer

 

• Disease control rate of 61% observed in evaluable Phase 2 patients treated with the same formulation in BriaCell’s pivotal Phase 3 study
• Disease control rate of 50% in evaluable patients treated with the Phase 3 formulation who failed prior antibody-drug conjugate (ADC) therapy
• Notable responder had failed 4 prior therapies including ADC therapy with metastatic liver tumor “no longer observed” following BriaCell treatment

https://www.globenewswire.com/news-release/2024/02/07/2825162/0/en/BriaCell-Announces-Strong-Clinical-Data-in-Breast-Cancer-Patients-Reports-Another-Notable-Responder-Case.html